ATP10B

Summary

ATP10B (ATPase phospholipid transporting 10B (putative), HGNC:13543) is a protein-coding gene on chromosome 5q34, encoding Phospholipid-transporting ATPase VB (O94823). Catalytic component of a P4-ATPase flippase complex, which catalyzes the hydrolysis of ATP coupled to the transport of glucosylceramide (GlcCer) from the outer to the inner leaflet of lysosome membranes.

Enables glycosylceramide flippase activity and phosphatidylcholine flippase activity. Involved in lysosomal membrane organization. Located in endoplasmic reticulum; late endosome membrane; and lysosomal membrane. Part of phospholipid-translocating ATPase complex.

Source: NCBI Gene 23120 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 270 total — 1 pathogenic
• MANE Select transcript: NM_025153

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13543
Approved symbol	ATP10B
Name	ATPase phospholipid transporting 10B (putative)
Location	5q34
Locus type	gene with protein product
Status	Approved
Aliases	ATPVB, KIAA0715, FLJ21477
Ensembl gene	ENSG00000118322
Ensembl biotype	protein_coding
OMIM	619791
Entrez	23120

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 5 protein_coding_CDS_not_defined, 4 retained_intron, 4 protein_coding

ENST00000326831, ENST00000327245, ENST00000517802, ENST00000517815, ENST00000518411, ENST00000520098, ENST00000520108, ENST00000520975, ENST00000521033, ENST00000522169, ENST00000523758, ENST00000642502, ENST00000943128

RefSeq mRNA: 9 — MANE Select: NM_025153 NM_001366652, NM_001366653, NM_001366654, NM_001366655, NM_001366656, NM_001366657, NM_001366658, NM_001410822, NM_025153

CCDS: CCDS43394, CCDS93811

Canonical transcript exons

ENST00000327245 — 26 exons

Exon	Start	End
ENSE00000768793	160589592	160589696
ENSE00000768795	160591059	160591139
ENSE00000768797	160598770	160598970
ENSE00000768799	160602577	160602702
ENSE00000768803	160606765	160607086
ENSE00000768805	160612741	160612925
ENSE00000768807	160615838	160615964
ENSE00000768809	160617864	160617973
ENSE00000768811	160620347	160620950
ENSE00001023039	160622394	160622585
ENSE00001085854	160569496	160569683
ENSE00001230569	160634354	160634606
ENSE00001337977	160632129	160632367
ENSE00001342125	160563120	160565900
ENSE00001411810	160785559	160785803
ENSE00001421415	160716909	160717034
ENSE00001474066	160688760	160688943
ENSE00001614134	160603965	160604041
ENSE00003466681	160644138	160644244
ENSE00003467494	160640461	160640592
ENSE00003479520	160670463	160670667
ENSE00003514972	160687800	160688094
ENSE00003538189	160686079	160686273
ENSE00003636342	160636182	160636309
ENSE00003648837	160649171	160649256
ENSE00003846336	160851941	160852211

Expression profiles

Bgee: expression breadth ubiquitous, 220 present calls, max score 98.69.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.5990 / max 112.0587, expressed in 156 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
64648	0.8218	89
64646	0.2674	82
64642	0.1866	28
64647	0.1284	44
64643	0.0804	18
64649	0.0348	25
64645	0.0312	20
64641	0.0251	13
64644	0.0232	12

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of sigmoid colon	UBERON:0004993	98.69	gold quality
colonic mucosa	UBERON:0000317	98.46	gold quality
palpebral conjunctiva	UBERON:0001812	98.09	gold quality
rectum	UBERON:0001052	96.52	gold quality
nasal cavity epithelium	UBERON:0005384	94.98	gold quality
ileal mucosa	UBERON:0000331	94.27	gold quality
corpus callosum	UBERON:0002336	91.17	gold quality
pancreatic ductal cell	CL:0002079	91.11	gold quality
buccal mucosa cell	CL:0002336	90.76	gold quality
cauda epididymis	UBERON:0004360	90.66	gold quality
duodenum	UBERON:0002114	90.56	gold quality
jejunal mucosa	UBERON:0000399	90.50	gold quality
esophagus squamous epithelium	UBERON:0006920	89.59	gold quality
mucosa of transverse colon	UBERON:0004991	89.16	gold quality
gingival epithelium	UBERON:0001949	88.86	gold quality
sural nerve	UBERON:0015488	88.58	gold quality
epithelium of esophagus	UBERON:0001976	88.28	gold quality
squamous epithelium	UBERON:0006914	88.25	gold quality
gingiva	UBERON:0001828	88.17	gold quality
mammalian vulva	UBERON:0000997	88.04	gold quality
inferior vagus X ganglion	UBERON:0005363	87.67	gold quality
epithelial cell of pancreas	CL:0000083	87.63	silver quality
gall bladder	UBERON:0002110	87.25	gold quality
inferior olivary complex	UBERON:0002127	87.24	gold quality
subthalamic nucleus	UBERON:0001906	86.96	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	85.02	gold quality
oral cavity	UBERON:0000167	84.89	gold quality
corpus epididymis	UBERON:0004359	84.75	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	84.48	gold quality
tongue squamous epithelium	UBERON:0006919	84.33	silver quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-111727	yes	1105.25
E-ANND-3	yes	7.88
E-MTAB-6379	no	16.31

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GLI2

miRNA regulators (miRDB)

129 targeting ATP10B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-6744-5P	99.93	66.82	748
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-129-5P	99.88	70.26	3273
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-6124	99.87	69.78	3551
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-3913-5P	99.78	67.26	968

Literature-anchored findings (GeneRIF, showing 4)

• Mutated ATP10B increases Parkinson’s disease risk by compromising lysosomal glucosylceramide export. (PMID:32172343)
• Genetic analysis of ATP10B for Parkinson’s disease in Japan. (PMID:34091411)
• The lipid flippase ATP10B enables cellular lipid uptake under stress conditions. (PMID:38086447)
• Role of ATP10B in Parkinson disease in a cohort from southern Spain. (PMID:38754220)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	atp10b	ENSDARG00000076230
mus_musculus	Atp10b	ENSMUSG00000055415
rattus_norvegicus	Atp10b	ENSRNOG00000003781
drosophila_melanogaster	CG9981	FBGN0030746
drosophila_melanogaster	CG4301	FBGN0030747
drosophila_melanogaster	CG31729	FBGN0051729
caenorhabditis_elegans	tat-5	WBGENE00009498
caenorhabditis_elegans		WBGENE00017174

Paralogs (13): ATP9A (ENSG00000054793), ATP11B (ENSG00000058063), ATP11A (ENSG00000068650), ATP8B1 (ENSG00000081923), ATP11C (ENSG00000101974), ATP8B4 (ENSG00000104043), ATP8A1 (ENSG00000124406), ATP8B3 (ENSG00000130270), ATP8A2 (ENSG00000132932), ATP8B2 (ENSG00000143515), ATP10D (ENSG00000145246), ATP9B (ENSG00000166377), ATP10A (ENSG00000206190)

Protein

Protein identifiers

Phospholipid-transporting ATPase VB — O94823 (reviewed: O94823)

Alternative names: ATPase class V type 10B, P4-ATPase flippase complex alpha subunit ATP10B

All UniProt accessions (3): A0A2R8YDI5, O94823, Q2YDW8

UniProt curated annotations — full annotation on UniProt →

Function. Catalytic component of a P4-ATPase flippase complex, which catalyzes the hydrolysis of ATP coupled to the transport of glucosylceramide (GlcCer) from the outer to the inner leaflet of lysosome membranes. Plays an important role in the maintenance of lysosome membrane integrity and function in cortical neurons.

Subunit / interactions. Component of a P4-ATPase flippase complex which consists of a catalytic alpha subunit ATP10B and an accessory beta subunit TMEM30A.

Subcellular location. Late endosome membrane. Lysosome membrane. Endoplasmic reticulum membrane.

Tissue specificity. Expressed in predominantly in brain structures including medulla oblongata, substantia nigra and basal ganglia. Expressed in the gastrointestinal system with highest levels in the small intestine and colon. Also expressed at low levels in testis and thymus.

Post-translational modifications. Autophosphorylated at the conserved aspartate of the P-type ATPase signature sequence.

Similarity. Belongs to the cation transport ATPase (P-type) (TC 3.A.3) family. Type IV subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
O94823-1	A	yes
O94823-2	B
O94823-3	C

RefSeq proteins (5): NP_001353581, NP_001353584, NP_001353586, NP_001397751, NP_079429* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001757	P_typ_ATPase	Family
IPR006539	P-type_ATPase_IV	Family
IPR008250	ATPase_P-typ_transduc_dom_A_sf	Homologous_superfamily
IPR018303	ATPase_P-typ_P_site	PTM
IPR023214	HAD_sf	Homologous_superfamily
IPR023298	ATPase_P-typ_TM_dom_sf	Homologous_superfamily
IPR023299	ATPase_P-typ_cyto_dom_N	Homologous_superfamily
IPR032630	P_typ_ATPase_c	Domain
IPR032631	P-type_ATPase_N	Domain
IPR036412	HAD-like_sf	Homologous_superfamily
IPR044492	P_typ_ATPase_HD_dom	Domain

Pfam: PF13246, PF16209, PF16212

Enzyme classification (BRENDA):

• EC 7.6.2.1 — P-type phospholipid transporter (BRENDA: 22 organisms, 260 substrates, 62 inhibitors, 53 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

4 substrates with measured Km, best-characterized 4. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.016–2.215	41
P-NITROPHENYL PHOSPHATE	1.17–1.46	3
ACETYL PHOSPHATE	1.03–1.31	2
1-PALMITOYL-2-OLEOYL-SN-GLYCERO-3-PHOSPHO-L-SERI	0.111	1

Catalyzed reactions (Rhea), 1 shown:

• a beta-D-glucosyl-(1<->1’)-N-acylsphing-4-enine(out) + ATP + H2O = a beta-D-glucosyl-(1<->1’)-N-acylsphing-4-enine(in) + ADP + phosphate + H(+) (RHEA:66036)

UniProt features (69 total): binding site 18, sequence variant 16, topological domain 11, transmembrane region 10, region of interest 3, compositionally biased region 3, splice variant 3, mutagenesis site 2, chain 1, active site 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O94823-F1	71.60	0.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 433 (4-aspartylphosphate intermediate)

Ligand- & substrate-binding residues (18): 433; 433; 434; 435; 435; 724; 766; 790; 835; 915; 916; 917 …

Mutagenesis-validated functional residues (2):

Position	Phenotype
210	loss of atpase flippase activity.
433	abolishes autophosphorylation and atpase flippase activity.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-936837	Ion transport by P-type ATPases
R-HSA-382551	Transport of small molecules
R-HSA-983712	Ion channel transport

MSigDB gene sets: 172 (showing top): MORF_FLT1, GOBP_VACUOLE_ORGANIZATION, GOCC_VACUOLAR_MEMBRANE, GOBP_REGULATION_OF_MEMBRANE_LIPID_DISTRIBUTION, MORF_RAD51L3, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, WEI_MYCN_TARGETS_WITH_E_BOX, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, MORF_IL4, MORF_THPO, TGGNNNNNNKCCAR_UNKNOWN, GOBP_PHOSPHOLIPID_TRANSPORT, GOBP_LYTIC_VACUOLE_ORGANIZATION, GOBP_MEMBRANE_ORGANIZATION, YY1_01

GO Biological Process (5): phospholipid translocation (GO:0045332), lysosomal membrane organization (GO:0097212), lipid transport (GO:0006869), phospholipid transport (GO:0015914), lipid translocation (GO:0034204)

GO Molecular Function (10): magnesium ion binding (GO:0000287), ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), ATPase-coupled intramembrane lipid carrier activity (GO:0140326), phosphatidylcholine flippase activity (GO:0140345), glycosylceramide flippase activity (GO:0140351), nucleotide binding (GO:0000166), transporter activity (GO:0005215), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (10): lysosomal membrane (GO:0005765), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), membrane (GO:0016020), late endosome membrane (GO:0031902), phospholipid-translocating ATPase complex (GO:1990531), lysosome (GO:0005764), endosome (GO:0005768), endomembrane system (GO:0012505)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Ion channel transport	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
lipid transport	2
ATP-dependent activity	2
endomembrane system	2
cellular anatomical structure	2
phospholipid transport	1
lipid translocation	1
lysosome organization	1
membrane organization	1
transport	1
lipid localization	1
organophosphate ester transport	1
regulation of membrane lipid distribution	1
metal ion binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ribonucleoside triphosphate phosphatase activity	1
intramembrane lipid carrier activity	1
phosphatidylcholine intramembrane carrier activity	1
glycerophospholipid flippase activity	1
sphingolipid intramembrane carrier activity	1
flippase activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
molecular_function	1
binding	1
cation binding	1
lysosome	1
lytic vacuole membrane	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
membrane	1
cell periphery	1
late endosome	1
endosome membrane	1
transporter complex	1
lytic vacuole	1
cytoplasmic vesicle	1

Protein interactions and networks

STRING

960 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ATP10B	CDC50A	Q9NV96	615
ATP10B	CDC50B	Q3MIR4	520
ATP10B	ATP10A	O60312	439
ATP10B	ATP10D	Q9P241	405
ATP10B	VPS13C	Q709C8	379
ATP10B	TEKT5	Q96M29	355
ATP10B	TPBGL	P0DKB5	344
ATP10B	F5GXT2	F5GXT2	327
ATP10B	PLA2G6	O60733	317
ATP10B	MAST4	O15021	310
ATP10B	OR5P2	Q8WZ92	305
ATP10B	PKD2L2	Q9NZM6	305
ATP10B	THG1L	Q9NWX6	293
ATP10B	SH3TC1	Q8TE82	291
ATP10B	ATP9B	O43861	290

IntAct

3 interactions, top by confidence:

A	B	Type	Score
ATP10B	TMEM30A	psi-mi:“MI:0915”(physical association)	0.400
PHACTR3	KCNK3	psi-mi:“MI:0914”(association)	0.350

BioGRID (7): ATP10B (Affinity Capture-MS), ATP10B (Affinity Capture-MS), ATP10B (Positive Genetic), ATP11A (Cross-Linking-MS (XL-MS)), ATP10B (Affinity Capture-MS), ATP10B (Affinity Capture-MS), ATP10B (Affinity Capture-MS)

ESM2 similar proteins: A0A131MCZ8, A3KMI0, A6H8T7, A7T1N0, B1AWN4, B7ZC32, D3ZEY4, D3ZSI8, F4INY4, G0S196, O36028, O54827, O60312, O60353, O60423, O62852, O94823, P21441, P22717, P32660, P34586, P49619, P49620, Q01063, Q03603, Q09891, Q12675, Q2NKY8, Q38SD2, Q39017, Q3UHC2, Q5BJS0, Q5CZZ9, Q5R607, Q5ZI74, Q6P158, Q6P5D3, Q6P5E8, Q6UQ17, Q7L2E3

Diamond homologs: A1A4J6, A3FIN4, B1AWN4, C7EXK4, D4AA47, D4ABB8, F1Q4S1, G0S196, G2X7W6, G5EBH1, O36028, O43520, O43861, O54827, O60312, O60423, O94296, O94823, P32660, P39524, P40527, P57792, P70704, P98195, P98196, P98197, P98198, P98199, P98200, P98204, P98205, Q09891, Q10309, Q12675, Q148W0, Q29449, Q37145, Q5BL50, Q6DFW5, Q6UQ17

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

270 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	222
Likely benign	19
Benign	4

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
441920	GRCh37/hg19 5p15.33-q35.3(chr5:113577-180719789)	Pathogenic

SpliceAI

4863 predictions. Top by Δscore:

Variant	Effect	Δscore
5:160602572:CTT:C	donor_loss	1.0000
5:160602573:TTACC:T	donor_loss	1.0000
5:160602574:TAC:T	donor_loss	1.0000
5:160602575:A:AC	donor_gain	1.0000
5:160602575:AC:A	donor_gain	1.0000
5:160602576:C:CA	donor_gain	1.0000
5:160602576:CC:C	donor_gain	1.0000
5:160602576:CCA:C	donor_gain	1.0000
5:160602576:CCACG:C	donor_gain	1.0000
5:160602699:CAGC:C	acceptor_gain	1.0000
5:160602700:AGCC:A	acceptor_loss	1.0000
5:160602701:GC:G	acceptor_gain	1.0000
5:160602702:CC:C	acceptor_gain	1.0000
5:160602702:CCTG:C	acceptor_loss	1.0000
5:160602703:C:CC	acceptor_gain	1.0000
5:160602704:T:G	acceptor_loss	1.0000
5:160603959:CAATA:C	donor_loss	1.0000
5:160603960:AATAC:A	donor_loss	1.0000
5:160603962:TA:T	donor_loss	1.0000
5:160603963:A:C	donor_loss	1.0000
5:160604038:TCAC:T	acceptor_gain	1.0000
5:160604039:CAC:C	acceptor_gain	1.0000
5:160604039:CACC:C	acceptor_gain	1.0000
5:160604040:ACCTG:A	acceptor_loss	1.0000
5:160604042:C:CC	acceptor_gain	1.0000
5:160604043:T:A	acceptor_loss	1.0000
5:160606767:A:AC	donor_gain	1.0000
5:160606817:A:AC	donor_gain	1.0000
5:160606818:C:CC	donor_gain	1.0000
5:160606818:CT:C	donor_gain	1.0000

AlphaMissense

9644 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:160634437:T:G	D433A	0.999
5:160604026:T:A	D1059V	0.998
5:160604026:T:G	D1059A	0.998
5:160620465:A:C	F766L	0.998
5:160620465:A:T	F766L	0.998
5:160620467:A:G	F766L	0.998
5:160620600:G:C	S721R	0.998
5:160620600:G:T	S721R	0.998
5:160620602:T:G	S721R	0.998
5:160634429:C:A	G436W	0.998
5:160634437:T:A	D433V	0.998
5:160634438:C:G	D433H	0.998
5:160569651:G:C	S1261R	0.997
5:160569651:G:T	S1261R	0.997
5:160569653:T:G	S1261R	0.997
5:160604025:A:C	D1059E	0.997
5:160604025:A:T	D1059E	0.997
5:160604027:C:G	D1059H	0.997
5:160604028:A:C	N1058K	0.997
5:160604028:A:T	N1058K	0.997
5:160617913:A:G	L826P	0.997
5:160620392:C:G	G791R	0.997
5:160620393:C:A	K790N	0.997
5:160620393:C:G	K790N	0.997
5:160634393:A:G	C448R	0.997
5:160591086:G:C	S1206R	0.996
5:160591086:G:T	S1206R	0.996
5:160591088:T:G	S1206R	0.996
5:160604041:C:T	G1054D	0.996
5:160606773:A:G	L1051P	0.996

dbSNP variants (sampled 300 via entrez): RS1000003527 (5:160596438 A>T), RS1000049944 (5:160650603 T>C), RS1000068161 (5:160834780 G>A,C), RS1000068308 (5:160703033 A>G), RS1000069330 (5:160644697 A>G), RS1000087073 (5:160813159 C>T), RS1000101103 (5:160611354 CCTT>C), RS1000102543 (5:160924327 C>A), RS1000103460 (5:160772309 T>A,C), RS1000124431 (5:160782995 T>A,G), RS1000125543 (5:160901297 T>A), RS1000128318 (5:160799641 A>G), RS1000134271 (5:160823178 G>A,C), RS1000136643 (5:160777583 C>A), RS1000141046 (5:160638923 T>C)

Disease associations

OMIM: gene MIM:619791 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary amenorrhea (MONDO:1060208)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST006053_3	Dermatomyositis or juvenile dermatomyositis	8.000000e-06
GCST010043_132	Asthma	1.000000e-12
GCST010172_12	Idiopathic downbeat nystagmus	6.000000e-06
GCST010572_1	Sweet taste preference	3.000000e-06
GCST010572_4	Sweet taste preference	5.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010156	sweet liking measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — P4 P-type ATPases: Phospholipid-transporting ATPases

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	3
bisphenol A	affects cotreatment, increases methylation, decreases expression, decreases reaction, increases abundance	2
ginger extract	decreases expression, decreases reaction, increases abundance	1
tungsten carbide	affects binding, decreases expression	1
sodium arsenate	decreases expression, increases abundance	1
trichostatin A	increases expression	1
sodium arsenite	increases expression	1
benzo(e)pyrene	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects cotreatment, affects response to substance	1
avobenzone	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
theaflavin-3,3’-digallate	affects expression	1
Temozolomide	increases expression	1
Zoledronic Acid	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Amphotericin B	increases expression	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Cobalt	affects binding, decreases expression	1
Lead	affects expression	1
Lipopolysaccharides	affects response to substance, increases expression, affects cotreatment	1
Methapyrilene	increases methylation	1
Oils, Volatile	increases abundance, decreases expression, decreases reaction	1
Testosterone	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Permethrin	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E3SX	BJ SiPS-D TH-TdTomato ATP10B KO clone #1	Induced pluripotent stem cell	Male
CVCL_E3SY	BJ SiPS-D TH-TdTomato ATP10B KO clone #4	Induced pluripotent stem cell	Male

Clinical trials (associated diseases)

1 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT07164248	Not specified	COMPLETED	Evaluation of Bone Mineral Density Indications and Outcomes in Female Adolescents: Implications for Early Detection of Osteopenia/Osteoporosis and Gynecologic Practice